Chan Y. Cheah
About
Chan Y. Cheah is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology.
According to data from OpenAlex, Chan Y. Cheah has authored 196 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Pathology and Forensic Medicine, 101 papers in Genetics and 89 papers in Oncology. Recurrent topics in Chan Y. Cheah's work include Lymphoma Diagnosis and Treatment (145 papers), Chronic Lymphocytic Leukemia Research (90 papers) and CAR-T cell therapy research (41 papers). Chan Y. Cheah is often cited by papers focused on Lymphoma Diagnosis and Treatment (145 papers), Chronic Lymphocytic Leukemia Research (90 papers) and CAR-T cell therapy research (41 papers). Chan Y. Cheah collaborates with scholars based in Australia, United States and United Kingdom. Chan Y. Cheah's co-authors include John F. Seymour, Nathan Fowler, Michael Wang, Andrew Wirth, Katharine L. Lewis, Toby A. Eyre, Tarec Christoffer El‐Galaly, H. Miles Prince, Loretta J. Nastoupil and Dai Chihara and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Chan Y. Cheah
169 papers receiving 3.5k citations
Hit Papers
Peers
Chan Y. Cheah
Hervé Ghesquières France
Andrew McMillan United Kingdom
Gustaaf W. van Imhoff Netherlands
Mats Jerkeman Sweden
Dok Hyun Yoon South Korea
Matthew J. Matasar United States
Karim Belhadj France
Marcel Reiser Germany
Bertram Glaß Germany
Judith Trotman Australia
Citations per year, relative to Chan Y. Cheah Chan Y. Cheah (= 1×)
peers
Hervé Ghesquières
Countries citing papers authored by Chan Y. Cheah
Since
Specialization
Citations
This map shows the geographic impact of Chan Y. Cheah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chan Y. Cheah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chan Y. Cheah more than expected).
Fields of papers citing papers by Chan Y. Cheah
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Chan Y. Cheah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chan Y. Cheah. The network helps show where Chan Y. Cheah may publish in the future.
Co-authorship network of co-authors of Chan Y. Cheah
This figure shows the co-authorship network connecting the top 25 collaborators of Chan Y. Cheah. A scholar is included among the top collaborators of Chan Y. Cheah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chan Y. Cheah. Chan Y. Cheah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Tam, Constantine S., Anna Maria Frustaci, Fontanet Bijou, et al.. (2024). Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory (R/R) Indolent NHL: Results from the Phase 1 CaDAnCe-101 Study. Blood. 144(Supplement 1). 1649–1649.
2.
Ghobadi, Armin, Joseph P. McGuirk, Paul Shaughnessy, et al.. (2024). CTX112, a Next-Generation Allogeneic CRISPR-Cas9 Engineered CD19 CAR T Cell with Novel Potency Edits: Data from Phase 1 Dose Escalation Study in Patients with Relapsed or Refractory B-Cell Malignancies. Blood. 144(Supplement 1). 4829–4829.
3.
Karimi, Yasmin, Catherine Thiéblemont, Hervé Ghesquières, et al.. (2024). Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7039–7039.
4.
Budde, Lihua E., Sarit Assouline, Laurie H. Sehn, et al.. (2024). Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study. Journal of Clinical Oncology. 42(19). 2250–2256.
5.
Tobin, Joshua W.D., Greg Hapgood, Anna Johnston, et al.. (2024). Diagnosis, management and follow‐up of follicular lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance . Internal Medicine Journal. 54(8). 1384–1395.
6.
Cheah, Chan Y. & John F. Seymour. (2023). Marginal zone lymphoma: 2023 update on diagnosis and management. American Journal of Hematology. 98(10). 1645–1657.
7.
Muehlenbein, Catherine E., Catherine C. Coombs, Nirav N. Shah, et al.. (2023). CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma & Leukemia. 23. S520–S520.
8.
Shortt, Jake, Peter Galettis, Chan Y. Cheah, et al.. (2023). A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma. Clinical Epigenetics. 15(1). 15–15.
9.
Wilson, Matthew R., et al.. (2023). How I manage mantle cell lymphoma: indolent versus aggressive disease. British Journal of Haematology. 201(2). 185–198.
10.
Minson, Adrian, Nada Hamad, Dipti Talaulikar, et al.. (2023). Death from mantle cell lymphoma limits sequential therapy, particularly after first relapse: Patterns of care and outcomes in a series from Australia and the United Kingdom. British Journal of Haematology. 204(2). 548–554.
11.
Villa, Diego, Aixiang Jiang, Carlo Visco, et al.. (2023). Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma. Blood Advances. 7(16). 4576–4585.
12.
Polizzotto, Mark N., Sam Milliken, Tara Cochrane, et al.. (2023). Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance. British Journal of Haematology. 201(5). 865–873.
13.
El‐Galaly, Tarec Christoffer, Diego Villa, Chan Y. Cheah, & Lars Christian Gormsen. (2022). Pre‐treatment total metabolic tumour volumes in lymphoma: Does quantity matter?. British Journal of Haematology. 197(2). 139–155.
14.
Budde, Elizabeth, Ajay K. Gopal, Won Seog Kim, et al.. (2021). A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. Blood. 138(Supplement 1). 132–132.
15.
Cheah, Chan Y., Wojciech Jurczak, Masa Lasica, et al.. (2021). TG-1701 A selective bruton tyrosine kinase (btk) inhibitor, as monotherapy and in combination with ublituximab and umbralisib (u2) in chronic lymphocytic leukemia (cll) and lymphoma. HemaSphere. 286–286.
16.
Matasar, Matthew J., Chan Y. Cheah, Dok Hyun Yoon, et al.. (2020). Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts. Blood. 136(Supplement 1). 45–46.
17.
Tan, Xuan, et al.. (2020). Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance. Leukemia & lymphoma. 61(14). 3412–3416.
18.
El‐Galaly, Tarec Christoffer, Chan Y. Cheah, & Diego Villa. (2019). Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. British Journal of Haematology. 186(3). 409–419.
19.
Barraclough, Allison, Musa Alzahrani, Mark Bishton, et al.. (2019). COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances. 3(13). 2013–2021.
20.
Barraclough, Allison, Musa Alzahrani, Mark Bishton, et al.. (2017). Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP ± Radiotherapy: An International Multi-Center Retrospective Study. Blood. 130. 415–415.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hervé Ghesquières Breakdown of academic impact, for papers by Andrew McMillan Breakdown of academic impact, for papers by Gustaaf W. van Imhoff Breakdown of academic impact, for papers by Mats Jerkeman Breakdown of academic impact, for papers by Dok Hyun Yoon Breakdown of academic impact, for papers by Matthew J. Matasar Breakdown of academic impact, for papers by Karim Belhadj Breakdown of academic impact, for papers by Marcel Reiser Breakdown of academic impact, for papers by Bertram Glaß Breakdown of academic impact, for papers by Judith Trotman